Avantogen and Innovate announce ASCO abstracts

June 08, 2006

Avantogen Limited ("Avantogen", ASX:ACU), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc ("Innovate"; IOVO:OTCBB), New York, today announced that 2 abstracts reporting on the evaluation of the use of RP101 in the treatment of patients with pancreatic cancer, were published at this weeks American Society of Medical Oncology (ASCO) Meeting in Atlanta, Georgia.

The first abstract (Fahrig et al, abstract no. 14000) reported the findings of a phase 1 pilot trial of 13 patients with advanced pancreatic cancer, which assessed the efficacy of RP101 in combination with gemcitabine and cisplatin, versus an appropriate historical control, consisting of patients who received the combination of gemcitabine and cisplatin only.

In this study all patients showed at least stable disease, and 33% of patients showed a partial remission. In the RP101 co-treatment group the median survival was significantly longer than that seen in the historical control group (447 days vs. 186 days, p=0.007) and time to progression (TTP) was also prolonged (280 days vs. 104 days, p=0.004). Ten of the 13 patients lived longer than one year and 4 remained alive, nearly two years after the first treatment.

The second abstract (Haenel et al, abstract no. 14075) reported the interim findings of an ongoing dose ranging study in which 22 patients with advanced pancreatic cancer received varying doses of RP101 in addition to fixed dose gemcitabine.

At the time of this interim analysis 36% of patients had been followed for less than 6 months and pooled data of those patients followed for 6 months or more showed 41% of patients were still alive and 23% had died. The median survival at this stage of follow up (95% CI) is 7.1 months and 14/22 patients (64%) were still alive. The 6 month survival rate (95% CI) is 0.69 (0.52, 0.85), which compares favorably with a recent large randomized trial in which patients who received gemcitabine alone had a median survival (95%CI) of 5.9 months (5.1-6.7). Median survival, progression free survival and time to progression will continue to be assessed in this ongoing trial and subsequent analyses reported accordingly. It was also observed that there may be a dose dependent increase in peak gemcitabine levels as a function of the dose of RP101. Lastly, to date, adverse events are consistent with those observed with gemcitabine or the underlying disease.

The new Chairman of Innovate, Dr. Richard Opara, said that "the publication of these abstracts demonstrates the continued progress in the development of RP101 and these studies provide us with data that can be used to plan the next phase of evaluation of this very interesting candidate which shows every prospect of becoming a significant therapeutic, offering hope to patients whose lives are drastically shortened by this grievous illness".
About Avantogen

Avantogen (formerly Australian Cancer Technology) is an international biotechnology company developing a broad oncology-related product portfolio. Aside from RP101, Avantogen's Pentrys® anticancer vaccine is being evaluated in prostate cancer patients in Phase IIb clinical studies. Recently, Avantogen merged its vaccine business, consisting of the Pentrys anti-cancer vaccine, and the GPI-0100 vaccine adjuvants, into Hawaii Biotech, Inc., a privately-held vaccine developer in Honolulu, Hawaii.
Hawaii Biotech develops state-of-the-art recombinant vaccines for common, deadly and incurable infectious diseases such as Influenza, West Nile encephalitis, and Dengue Fever. Avantogen is traded on the Australian Stock Exchange (ASX) under the symbol ACU. The company has established a Level 1 ADR stock program in the U.S. trading under the symbol AUCJY and also is listed on the Xetra exchange, the electronic trading system of the Frankfurt Stock Exchange, trading under the symbol CBS. For further information, visit www.Avantogen.com
Dr. Richard Opara, Executive Chairman
San Diego, CA, USA
Tel: +858-458-6807
Email: info@Avantogen.com

About Innovate

Innovate is an international biotechnology company developing a focused oncology related product candidate portfolio, including clinical evaluation of RP101 for patients for pancreatic cancer and preclinical evaluation two candidates, Capridine Beta in the setting of prostate cancer and an oral formulation of Paclitaxel. Innovate is traded on the OTC Bulletin Board under the symbol IOVO.OB. For further information, visit www.Avantogen.com
Chris Nowers, CEO
Innovate Oncology, Inc.
San Diego, CA USA
Tel: +858-458-6807
Email: info@Avantogen.com

Research Australia

Related Pancreatic Cancer Articles from Brightsurf:

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Nerves keep pancreatic cancer cells from starving
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients.

Pancreatic cancer: Subtypes with different aggressiveness discovered
To date, no targeted personalized therapies for pancreatic cancer exist.

Bringing the 'sticky' back to pancreatic cancer
A multidisciplinary team of researchers at Japan's Tohoku University has found that a gene regulator, called BACH1, facilitates the spread of pancreatic cancer to other parts of the body.

Does lung damage speed pancreatic cancer?
High levels of CO2 in the body, due to chronic respiratory disorders, may exacerbate pancreatic cancer, making it more aggressive and resistant to therapy.

Scientists have identified the presence of cancer-suppressing cells in pancreatic cancer
Researchers have identified cells containing a protein called Meflin that has a role in restraining the progression of pancreatic cancer.

Pancreatic cancer discovery reveals how the aggressive cancer fuels its growth
A new discovery about pancreatic cancer sheds light on how the cancer fuels its growth and may help explain how promising cancer drugs work -- and for whom they will fail.

Overcoming resistance in pancreatic cancer
In pancreatic cancer cells' struggle to survive, the cells choose alternative routes when their main pathways are blocked by drugs.

Exposing how pancreatic cancer does its dirty work
Pancreatic cancer is a puzzle -- tumors slough off cells into the bloodstream early in the disease, but the tumors themselves have almost no blood vessels in them.

Targeting cell division in pancreatic cancer
Study provides new evidence of synergistic effects of drugs that inhibit cell division and support for further clinical trials.

Read More: Pancreatic Cancer News and Pancreatic Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.